Literature DB >> 29598848

Dual Transforming Growth Factor-β and Programmed Death-1 Blockade: A Strategy for Immune-Excluded Tumors?

Claire Vanpouille-Box1, Silvia C Formenti2.   

Abstract

Tumors that elude infiltration by CD8+ T lymphocytes are particularly resistant to multiple forms of treatment, including immune checkpoint blockade. Stromal transforming growth factor (TGF)-β appears to play a key role in this process, potentially constituting a target for novel combinatorial regimens tackling immune-excluded neoplasms.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  PD-1; atezolizumab; microsatellite instability; mutational burden; tumor neoantigens; tumor organoids

Mesh：

Substances：

Year:  2018        PMID： 29598848      PMCID： PMC5972064          DOI： 10.1016/j.it.2018.03.002

Source DB:  PubMed          Journal:  Trends Immunol        ISSN： 1471-4906            Impact factor:   16.687


  9 in total

Review 1.  Regulation of the anti-tumour immune response by cancer-associated fibroblasts.

Authors:  James Harper; Richard C A Sainson
Journal:  Semin Cancer Biol       Date:  2014-01-07       Impact factor: 15.707

Review 2.  Immunoregulation by members of the TGFβ superfamily.

Authors:  WanJun Chen; Peter Ten Dijke
Journal:  Nat Rev Immunol       Date:  2016-11-25       Impact factor: 53.106

3.  TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity.

Authors:  Claire Vanpouille-Box; Julie M Diamond; Karsten A Pilones; Jiri Zavadil; James S Babb; Silvia C Formenti; Mary Helen Barcellos-Hoff; Sandra Demaria
Journal:  Cancer Res       Date:  2015-04-09       Impact factor: 12.701

Review 4.  Elements of cancer immunity and the cancer-immune set point.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Nature       Date:  2017-01-18       Impact factor: 49.962

5.  TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis.

Authors:  Daniele V F Tauriello; Sergio Palomo-Ponce; Diana Stork; Antonio Berenguer-Llergo; Jordi Badia-Ramentol; Mar Iglesias; Marta Sevillano; Sales Ibiza; Adrià Cañellas; Xavier Hernando-Momblona; Daniel Byrom; Joan A Matarin; Alexandre Calon; Elisa I Rivas; Angel R Nebreda; Antoni Riera; Camille Stephan-Otto Attolini; Eduard Batlle
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962

Review 6.  Monitoring immune-checkpoint blockade: response evaluation and biomarker development.

Authors:  Mizuki Nishino; Nikhil H Ramaiya; Hiroto Hatabu; F Stephen Hodi
Journal:  Nat Rev Clin Oncol       Date:  2017-06-27       Impact factor: 66.675

Review 7.  The biology and function of fibroblasts in cancer.

Authors:  Raghu Kalluri
Journal:  Nat Rev Cancer       Date:  2016-08-23       Impact factor: 60.716

Review 8.  Barriers to Radiation-Induced In Situ Tumor Vaccination.

Authors:  Erik Wennerberg; Claire Lhuillier; Claire Vanpouille-Box; Karsten A Pilones; Elena García-Martínez; Nils-Petter Rudqvist; Silvia C Formenti; Sandra Demaria
Journal:  Front Immunol       Date:  2017-03-13       Impact factor: 7.561

9.  TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Authors:  Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962
  9 in total
  13 in total

1.  Peripheral memory T cells specific for Arginase-1.

Authors:  Evelina Martinenaite; Shamaila Munir Ahmad; Inge Marie Svane; Mads Hald Andersen
Journal:  Cell Mol Immunol       Date:  2019-05-10       Impact factor: 11.530

Review 2.  VISTA: Coming of age as a multi-lineage immune checkpoint.

Authors:  M A ElTanbouly; E Schaafsma; R J Noelle; J L Lines
Journal:  Clin Exp Immunol       Date:  2020-02-04       Impact factor: 4.330

Review 3.  Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer.

Authors:  Giulia Petroni; Lewis C Cantley; Laura Santambrogio; Silvia C Formenti; Lorenzo Galluzzi
Journal:  Nat Rev Clin Oncol       Date:  2021-11-24       Impact factor: 66.675

4.  TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell-Mediated Regression of Pancreatic Cancer.

Authors:  Daniel R Principe; Alex Park; Matthew J Dorman; Sandeep Kumar; Navin Viswakarma; Jonathan Rubin; Carolina Torres; Ronald McKinney; Hidayatullah G Munshi; Paul J Grippo; Ajay Rana
Journal:  Mol Cancer Ther       Date:  2018-12-26       Impact factor: 6.009

Review 5.  Trials and tribulations of pancreatic cancer immunotherapy.

Authors:  Daniel R Principe; Murray Korc; Suneel D Kamath; Hidayatullah G Munshi; Ajay Rana
Journal:  Cancer Lett       Date:  2021-02-04       Impact factor: 9.756

Review 6.  MicroRNAs Are Key Molecules Involved in the Gene Regulation Network of Colorectal Cancer.

Authors:  Fangfang Yang; Guoyun Xuan; Yixin Chen; Lichao Cao; Min Zhao; Chen Wang; Erfei Chen
Journal:  Front Cell Dev Biol       Date:  2022-04-08

7.  Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients.

Authors:  Silvia C Formenti; Rachael E Hawtin; Neha Dixit; Erik Evensen; Percy Lee; Judith D Goldberg; Xiaochun Li; Claire Vanpouille-Box; Dörthe Schaue; William H McBride; Sandra Demaria
Journal:  J Immunother Cancer       Date:  2019-07-11       Impact factor: 13.751

Review 8.  Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor.

Authors:  Xianguang Bai; Ming Yi; Ying Jiao; Qian Chu; Kongming Wu
Journal:  Onco Targets Ther       Date:  2019-11-11       Impact factor: 4.147

9.  Activin A Promotes Regulatory T-cell-Mediated Immunosuppression in Irradiated Breast Cancer.

Authors:  Mara De Martino; Camille Daviaud; Julie M Diamond; Jeffrey Kraynak; Amandine Alard; Silvia C Formenti; Lance D Miller; Sandra Demaria; Claire Vanpouille-Box
Journal:  Cancer Immunol Res       Date:  2020-10-22       Impact factor: 12.020

10.  Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy.

Authors:  Daniel R Principe; Matthew Narbutis; Sandeep Kumar; Alex Park; Navin Viswakarma; Matthew J Dorman; Suneel D Kamath; Paul J Grippo; Melissa L Fishel; Rosa F Hwang; Dinesh Thummuri; Patrick W Underwood; Hidayatullah G Munshi; Jose G Trevino; Ajay Rana
Journal:  Cancer Res       Date:  2020-04-01       Impact factor: 13.312
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.